News & Updates
Filter by Specialty:
CVT risk higher after COVID-19 than COVID-19 mRNA vaccine
An observational study from Singapore has shown that the incidence of cerebral venous thrombosis (CVT) following SARS-CoV-2 infection is greater than that following receipt of an mRNA-based SARS-CoV-2 vaccine.
CVT risk higher after COVID-19 than COVID-19 mRNA vaccine
20 Apr 2022
US-guided corticosteroid injection relieves symptoms in hip OA
An ultrasound (US)-guided intra-articular hip injection of corticosteroid and local anaesthetic, administered with advice and education, results in a rapid and sustained symptom response for individuals with hip osteoarthritis (OA), a study has shown.
US-guided corticosteroid injection relieves symptoms in hip OA
20 Apr 2022
AF affects one-third of patients after cryptogenic stroke, TIA
Almost 30 percent of patients who experience a cryptogenic stroke or transient ischaemic attack (TIA) go on to develop atrial fibrillation (AF), most of them asymptomatic, according to results of the NOR-FIB* study presented at EHRA 2022.
AF affects one-third of patients after cryptogenic stroke, TIA
19 Apr 2022
Acute kidney, liver injury risks with remdesivir pinned to underlying SARS-CoV-2 infection
Treatment with remdesivir in patients hospitalized for COVID-19 does not appear to confer increased risks of acute kidney and liver injury, with a recent study showing that these risks are already elevated even before exposure to treatment and there is no further increase following remdesivir initiation.
Acute kidney, liver injury risks with remdesivir pinned to underlying SARS-CoV-2 infection
18 Apr 2022
Early molnupiravir use benefits unvaccinated COVID-19 outpatients
Early administration (ie, within 5 days after symptom onset) of the oral, small-molecule antiviral prodrug molnupiravir slashed the risk of hospitalization or death in at-risk, unvaccinated, nonhospitalized adults with mild-to-moderate COVID-19, findings from the phase III component of the phase II/III MOVe-OUT trial have shown.
